Novo Nordisk AS (NVO)
85.00
-18.44
(-17.83%)
USD |
NYSE |
Dec 20, 16:00
86.00
+1.00
(+1.18%)
After-Hours: 20:00
Novo Nordisk Enterprise Value: 374.83B for Dec. 20, 2024
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ascendis Pharma AS | 8.324B |
| Evaxion Biotech AS | 0.8149M |
| Amgen Inc | 192.96B |
| Viking Therapeutics Inc | 3.778B |
| Akari Therapeutics PLC | 22.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 4.023B |
| Revenue (Quarterly) | 10.51B |
| Total Expenses (Quarterly) | 5.525B |
| EPS Diluted (Quarterly) | 0.9019 |
| Gross Profit Margin (Quarterly) | 84.14% |
| Profit Margin (Quarterly) | 38.28% |
| Earnings Yield | 3.63% |
| Operating Earnings Yield | 4.54% |
| Normalized Earnings Yield | 3.631 |